Q1 Earnings Forecast for IPSC Issued By HC Wainwright

Century Therapeutics, Inc. (NASDAQ:IPSC) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Century Therapeutics in a report released on Tuesday, April 21st. HC Wainwright analyst M. Kapoor expects that the company will post earnings per share of ($0.22) for the quarter. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Century Therapeutics’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Century Therapeutics’ Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.00) EPS, Q1 2027 earnings at ($0.22) EPS, Q2 2027 earnings at ($0.23) EPS, Q3 2027 earnings at ($0.22) EPS, Q4 2027 earnings at ($0.21) EPS and FY2027 earnings at ($0.89) EPS.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04.

Other analysts have also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Century Therapeutics in a report on Monday, April 6th. Leerink Partners set a $2.00 price objective on shares of Century Therapeutics and gave the company a “market perform” rating in a research report on Friday, March 13th. Zacks Research lowered Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, March 12th. Wall Street Zen raised Century Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Finally, Piper Sandler lifted their target price on Century Therapeutics from $2.00 to $4.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Century Therapeutics has an average rating of “Hold” and a consensus target price of $4.25.

Century Therapeutics Trading Down 7.4%

IPSC opened at $2.26 on Thursday. The company’s 50 day moving average is $2.29 and its 200 day moving average is $1.47. The company has a market cap of $406.94 million, a price-to-earnings ratio of -16.14 and a beta of 1.66. Century Therapeutics has a 12-month low of $0.44 and a 12-month high of $3.04.

Institutional Trading of Century Therapeutics

Institutional investors have recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. purchased a new stake in Century Therapeutics during the 4th quarter valued at approximately $1,829,000. Spruce Street Capital LP purchased a new stake in Century Therapeutics in the 4th quarter worth $1,414,000. Two Sigma Investments LP lifted its stake in Century Therapeutics by 59.2% in the 3rd quarter. Two Sigma Investments LP now owns 911,446 shares of the company’s stock worth $454,000 after purchasing an additional 338,902 shares in the last quarter. GSA Capital Partners LLP boosted its holdings in shares of Century Therapeutics by 29.3% during the 3rd quarter. GSA Capital Partners LLP now owns 603,479 shares of the company’s stock valued at $301,000 after purchasing an additional 136,873 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Century Therapeutics by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 456,115 shares of the company’s stock valued at $454,000 after purchasing an additional 10,806 shares in the last quarter. Hedge funds and other institutional investors own 50.20% of the company’s stock.

Insiders Place Their Bets

In related news, insider Gregory Russotti sold 10,076 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $2.55, for a total value of $25,693.80. Following the completion of the transaction, the insider owned 515,427 shares of the company’s stock, valued at approximately $1,314,338.85. This represents a 1.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last ninety days, insiders have sold 17,921 shares of company stock valued at $45,458. Corporate insiders own 4.37% of the company’s stock.

Trending Headlines about Century Therapeutics

Here are the key news stories impacting Century Therapeutics this week:

• Positive Sentiment: HC Wainwright maintains a “Buy” rating and a $5.00 price target, which supports upside if clinical or partnership milestones are met. HC Wainwright note (Buy, $5 target)
• Neutral Sentiment: The firm released a full schedule of quarterly estimates (Q1–Q4 2026 and Q1–Q4 2027), showing fairly steady per-quarter losses in the ~$0.21–$0.23 range — useful guidance but not a near-term catalyst by itself. HC Wainwright quarterly EPS schedule
• Negative Sentiment: HC Wainwright’s FY2026 EPS forecast of ($1.00) and FY2027 forecast of ($0.89) are materially worse than the consensus (~($0.44)), implying deeper cash burn, greater financing/dilution risk and downward pressure on valuation. That divergence is the likely driver of the share weakness. HC Wainwright downside EPS outlook

About Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.